BridgeBio Oncology Therapeutics, Inc. - BBOT
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors LLC | 3.2% | 2,528,762 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors Holdings LP | 3.2% | 2,528,762 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel GP LLC | 3.2% | 2,528,762 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities LLC | 0.0% | 9,380 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities Group LP | 0.0% | 9,380 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities GP LLC | 0.0% | 9,380 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kenneth Griffin | 3.2% | 2,538,142 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Adage Capital Management, L.P. | 1.88% | 1,487,621 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Robert Atchinson | 1.88% | 1,487,621 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Phillip Gross | 1.88% | 1,487,621 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.